Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

Pharma: Be Prepared For Tougher Price Negotiations For IO Combos And Expansions In Europe

Payers are increasingly likely to implement new strategies to manage price negotiations for immuno-oncology combinations, as competition  heats up among the drug class. Mechanisms allowing for the negotiation of different prices for combination therapies do not exist at present, but payers insist that new tools must emerge.

ImmunoOncology Health Technology Assessment Pricing Strategies

Latest From Pricing Debate

Cost Concerns May Hinder Naloxone Co-Prescribing Ideas

US FDA estimates mandating naloxone co-prescriptions could dramatically increase spending to more than total estimated cost of opioid crisis itself; joint advisory committee to consider options to increase naloxone availability.
Neurology Pricing Debate

UK Inquiry Into ‘Unfair’ Orkambi Pricing Risks Pricing Confidentiality

The UK government has criticized Vertex for the company’s approach to pricing its cystic fibrosis drug Orkambi. In the meantime, a parliamentary inquiry that could expose sensitive pricing details moves forward.

Europe United Kingdom

Pfizer Price Increases Underscore Rebate Problem, HHS’ Hargan Says

The Trump Administration remains convinced that rebates lead to high list prices and that reform of the system is needed, US HHS Deputy Secretary Eric Hargan emphasizes.

Pricing Debate Pharmacy Benefit Management

Eisai Adds To Alzheimer's Arsenal With Anti-Tau Drug

It is a field littered with failures but Eisai remains hopeful that its pipeline of candidates for Alzheimer's disease, which has just been added to, gives the firm a number of shots at getting a disease-modifying agent to market.

Neurology Pricing Debate

Will Mexico's COFEPRIS Dissolve Under New Presidency?

Newly inaugurated Mexican President Andrés Manuel López Obrador may restructure drug regulator in quest to centralize government's public health services.
Pricing Debate Regulation

CVS ‘Guaranteed Net Cost’ Program Is Alternative To High Price/High Rebate Model

Program likely to generate fewer rebates so it remains to be seen whether payers will embrace the new model in a big way.

Pharmacy Benefit Management Reimbursement

Retail Drug Spending In US Flat For 2017 Due Mainly To 'Non-Price' Factors

Drop in number of prescriptions dispensed for opioids contributed to minimal spending growth for retail prescription drugs in 2017, according to latest CMS National Health Expenditures Report.

Reimbursement Medicare

NGOs Continue Fight To Remove Key Patent On Gilead’s Sovaldi

NGOs are continuing their efforts to pave the way for lower-cost generic versions of Gilead’s breakthrough hepatitis C treatment Sovaldi and have appealed a decision by the European Patent Office to uphold a key patent relating to the drug.

Intellectual Property Market Access

Drug Pricing In The Next Senate: Incoming Finance Chair Grassley Outlines Priorities

A key figure in determining what Rx bills advance in Congress, Grassley recently expressed interest in working with House Democrats in a floor speech on his drug pricing priorities.

Pricing Debate Legislation
See All
Advertisement
UsernamePublicRestriction

Register